89bio Inc (ETNB) - Total Liabilities
Based on the latest financial reports, 89bio Inc (ETNB) has total liabilities worth $81.75 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of 89bio Inc to evaluate the company's liquid asset resilience ratio.
89bio Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how 89bio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 89bio Inc assets under control.
89bio Inc Competitors by Total Liabilities
The table below lists competitors of 89bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank of N.T. Butterfield & Son Ltd
NYSE:NTB
|
USA | $13.29 Billion |
|
Medco Energi Internasional Tbk
JK:MEDC
|
Indonesia | Rp5.87 Billion |
|
China Railway Materials Co Ltd
SHE:000927
|
China | CN¥10.05 Billion |
|
ABL Bio Inc
KQ:298380
|
Korea | ₩99.78 Billion |
|
GQG Partners Inc
AU:GQG
|
Australia | AU$61.28 Million |
|
Compania Cervecerias Unidas SA
SN:CCU
|
Chile | CL$2.03 Trillion |
|
Hilltop Holdings Inc
NYSE:HTH
|
USA | $13.39 Billion |
|
Aadhar Housing Finance Ltd
NSE:AADHARHFC
|
India | Rs181.89 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down 89bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ETNB equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 89bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 89bio Inc (2018–2024)
The table below shows the annual total liabilities of 89bio Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $77.90 Million | +29.91% |
| 2023-12-31 | $59.96 Million | +33.27% |
| 2022-12-31 | $44.99 Million | +23.38% |
| 2021-12-31 | $36.47 Million | +349.46% |
| 2020-12-31 | $8.11 Million | +44.64% |
| 2019-12-31 | $5.61 Million | -79.55% |
| 2018-12-31 | $27.43 Million | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more